Chipscreen(SH:688321) Ge Long Hui A P P·2026-01-26 09:35Core Viewpoint - Microchip Biotech (688321.SH) expects to achieve an annual revenue of approximately 910.08 million yuan in 2025, representing a year-on-year growth of about 38.32% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan in 2025, an increase of about 168.03 million yuan compared to the previous year, marking a turnaround from losses to profits [1] - The expected net profit excluding non-recurring gains and losses is around 38.14 million yuan [1] Product Performance - The product Sigleptin Sodium has shown significant commercial success with a sales revenue increase of approximately 123% year-on-year, driven by its unique clinical value in "diabetes and liver management" and enhanced distribution through self-operated, strategic partners, and new retail channels [1] - The product Sidabenamine has gained recognition for its clinical value, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]